MacroGenics (MGNX)
(Real Time Quote from BATS)
$4.26 USD
-0.02 (-0.35%)
Updated Jul 10, 2024 03:20 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 181 - 200 ( 362 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Margetuximab + Keytruda Active in Gastric Cancer; But Path Forward Unclear; Impact on Stock Likely to be Muted
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology -ASCO Presentations Roundup for Covered Companies: Part 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Giving Us Something to Talk About - Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
1Q18 Financials; Margetuximab Gastric Cancer Update at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology - ASCO Abstract Titles Released
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Transitioning From a "Shots on Goal" Story to a "Shots in Goal" Company; Initiating With a Buy and $38 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Q4YE17 Financials; Multiple Shots on Goal with Pipeline in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Marge? Shows Promise in Gastric Cancer, Shares Attractive Going into 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Flotetuzumab Update; Encouraging Early Data for CD123- Targeted DART
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D